DeepMed Research

Jiangsu Simcere Pharmaceutical Co,. Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Phase 3

Completed

Conditions: Insomnia Disorder

Interventions: Drug: Placebo
Drug: Daridorexant

First Posted Date: 2023-08-24

Last Posted Date: 2024-10-30

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 206

Registration Number: NCT06010693

Locations: 🇨🇳
The Second People's Hospital Of Hefei, Hefei, Anhui, China
🇨🇳
Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳
Beijing Huilongguan Hospital, Beijing, Beijing, China

and more 30 locations

Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects

Phase 1

Recruiting

Conditions: Elder

Interventions: Drug: SIM0417/Ritonavir

First Posted Date: 2023-04-24

Last Posted Date: 2023-04-24

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT05826249

Locations: 🇨🇳
Shandong First Medical University, Jinan, Shandong, China

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

Phase 1

Terminated

Conditions: Locally Advanced Unresectable or Metastatic Solid Tumor

Interventions: Drug: SIM0237

First Posted Date: 2023-03-23

Last Posted Date: 2024-12-20

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 192

Registration Number: NCT05781360

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸
NYU Langone, New York, New York, United States
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 6 locations

Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir

Phase 1

Not yet recruiting

Conditions: Renal Impairment
Hepatic Impairment

Interventions: Drug: SIM0417 600 mg; Ritonavir100 mg
Drug: SIM0417 375 mg; Ritonavir100 mg
Drug: SIM0417 750 mg; Ritonavir100 mg

First Posted Date: 2023-02-16

Last Posted Date: 2023-03-08

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT05731804

Locations: 🇨🇳
Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Escalating Doses of SIM0348 as a Single Agent in Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SIM0348

First Posted Date: 2023-02-08

Last Posted Date: 2023-02-08

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 68

Registration Number: NCT05718219

Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

First Posted Date: 2022-12-27

Last Posted Date: 2023-02-21

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT05665647

Locations: 🇨🇳
Shandong First Medical University, Jinan, Shandong, China

A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Cutaneous T-cell Lymphoma (CTCL)

Interventions: Drug: SIM1811-03

First Posted Date: 2022-10-06

Last Posted Date: 2022-10-07

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT05569057

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Henry Ford Health, Detroit, Michigan, United States
🇺🇸
NYU Lagone Health, New York, New York, United States

and more 3 locations

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

Phase 1

Recruiting

Conditions: Solid Tumor
Non Hodgkin Lymphoma

Interventions: Drug: SCR-6920 capsule

First Posted Date: 2022-09-06

Last Posted Date: 2022-09-06

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 122

Registration Number: NCT05528055

Locations: 🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China

A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: SIM0417
Drug: Placebo

First Posted Date: 2022-08-18

Last Posted Date: 2023-05-06

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 1208

Registration Number: NCT05506176

Locations: 🇨🇳
Hefei First People's Hospital, Hefei, Anhui, China
🇨🇳
Chongqing Public Health Medical Center, Chongqing, Chongqing, China
🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

and more 32 locations

Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: SIM0417

First Posted Date: 2022-07-27

Last Posted Date: 2022-10-03

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 6

Registration Number: NCT05475834

Locations: 🇨🇳
Shandong First Medical University, Jinan, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy